Embolization Particles Market Size to Reach USD 3.65 Billion by 2034
The global embolization particles market size is calculated at USD 1.15 billion in 2024, grows to USD 1.29 billion in 2025, and is projected to reach around USD 3.65 billion by 2034, accelerating at a CAGR of 12.23% from 2025 to 2034. The embolization particles market growth is driven by the continuous advancements in medical technology, increased demand for minimally invasive procedures and supportive regulatory frameworks.
Embolization particles, also known as embolic agents, are tiny substances utilized for blocking blood flow in a blood vessel during medical procedures. Embolization treatments are widely utilized in conditions such as arteriovenous malformations (AVMs), cancer, peripheral vascular diseases and uterine fibroids. Technological advancements such as improvements in catheter designs and materials used for making particles in embolization products and procedures are enhancing the safety and efficacy of these treatments.
Rising regulatory approvals, increased investments for advancing healthcare infrastructure, ongoing research activities, innovative product launches and advancements in delivery systems are the factors driving the growth of the embolization particles market. Growing emphasis on providing access to effective and quality healthcare to overall population and favourable reimbursement policies are creating opportunities for market expansion in the future.
AI-powered systems can provide real-time insights by assisting in navigation and targeting to interventionalists throughout the embolization procedures, especially in complex cases. AI algorithms can assist in identification of patients at high risk of complications or requiring different treatment approach by analyzing patient demographics, imaging data and several other clinical parameters. Development and optimization of embolization particles by implementing AI algorithms can enable creation of novel embolization agents with enhanced safety, efficacy and targeting capabilities. Manufacturers are incorporating AI in quality control for monitoring particle size, shape and other characteristics of particles during manufacturing processes as well as for predictive maintenance of equipment for reducing downtimes and enabling proactive maintenance.
| Report Coverage | Details |
| Market Size in 2025 | USD 1.29 Billion |
| Market Size by 2034 | USD 3.65 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 12.23% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Product Type, Application, and Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Guerbet, Terumo, BTG International Ltd, Boston Scientific Corporation, Medtronic, Sirtex, Merit Medical |
Drivers
Rising Prevalence of Target Diseases
Increased prevalence of diseases such as various types of cancers, peripheral vascular diseases, uterine fibroids and need for controlling haemorrhage in severe traumatic conditions is generating a large patient pool across the globe need effective treatments. Growing preference of healthcare providers and patients for minimally invasive procedures such as embolization to reduce patient trauma, accelerating time of recovery, shortening hospital stays and improving patient outcomes is driving the market growth.
High Costs of Devices and Procedures
Embolization procedures are highly expensive as it involves the use of sophisticated medical devices, specialized embolic agents and also require imaging guidance. Additionally, costs associated with hospitals stays and other fees is unaffordable for most patients, especially in low and middle-income countries which can significantly restrain the growth of the embolization particles market.
Expanded Therapeutic Applications
With the ongoing advancements in medical technology, researchers and pharmaceutical companies are focused on expanding the use of embolization particles for new therapeutic indications. Research activities and clinical trials are being carried for various applications such as for benign prostate hyperplasia (BPH), chronic pain management such as Genicular Artery Embolization (GAE) for osteoarthritis, chronic subdural hematoma (CSDH), in pelvic venous congestion syndrome, diabetic foot ulcers and hemorrhoidal disease. These expanding applications as well as continuous advancements in developing innovative and specialized embolization particles is creating lucrative opportunities for market growth.
What Made Radioembolization the Dominant Segment in 2024?
By product type, the radioembolization segment dominated the market in 2024. Radioembolization (TARE) is a vital treatment option applied in various types of cancers, majorly in hepatocellular carcinoma and metastatic liver cancers as well as in several peripheral vascular conditions, uterine fibroids and aneurysms. Increased preference towards minimally invasive procedures, continuous innovations in radioembolization spheres, advancements in imaging modalities, improvements in catheter technology and access to sophisticated software tools are driving the market dominance of this segment.
By product type, the drug eluting beads segment is expected to register the fastest CAGR during the predicted timeframe. Rising cases of vascular diseases, various types of cancers and trauma incidents are driving the demand for drug- eluting beads (DEB). Transarterial Chemoembolization with drug-eluting beads (DEB-TACE) is considered a high effective option for treating cancers such as neuroendocrine tumors and renal cell carcinoma.
DEB embolization being a minimally invasive procedure offers multiple benefits such as lower complication rates, less scarring and trauma, reduced recovery times and decreased systemic toxicity. Furthermore, increased demand for interventional radiology procedures, expanding applications based on real world clinical evidence, rising investments for advancing healthcare infrastructure and shift towards personalized treatments are the factors anticipated to propel the market growth of this segment in the upcoming years.
Why Did the Oncology Segment Dominate in 2024?
By application, the oncology segment held the largest market share in 2024. Globally rising burden of various types of cancer, especially kidney cancer, liver cancer and metastatic colorectal cancers is creating the demand for minimally invasive, safe and effective therapeutic approaches such as embolization procedures. Continuous advancements and innovation in embolization particles such as delivering chemotherapy drugs through DEBs, using radioembolization spheres containing radioactive isotopes for supplying localized radiation to the tumor as well as development of biocompatible materials getting absorbed in the body over time are improving outcomes in cancer patients.
Additionally, increased demand for minimally invasive techniques, surging healthcare expenditure in emerging economies, and significant investments in research and development activities by various companies and governments are the factors boosting market growth. Increased awareness and focus on early detection of cancer with advanced diagnostic tools as well as favourable reimbursement policies are expanding patient access and adoption of these embolization particles. Key market companies are engaging in strategic collaborations, mergers and acquisitions for expanding the global reach of their business and strengthening their product portfolios.
By application, the peripheral vascular diseases segment is expected to show the fastest growth over the forecast period. Peripheral vascular diseases (PVDs) such as peripheral artery disease (PAD), aneurysms, arteriovenous malformations (AVMs) and other vascular anomalies are rising globally due to various factors such as increased diabetes rates, aging populations and smoking habits. Embolization particles offer a minimally invasive approach for addressing many types of PVD conditions with benefits such as reduced pain, faster recovery times, less scarring and minimum complications leading to increased patient compliance and adoption of these procedures. Additionally, advancements in embolization particle characteristics, use of liquid embolic agents, increased research into bioactive coils and coated particles, development of precise catheter technology for improving delivery of particles are the factors creating opportunities for market growth.
How is North America Dominating the Embolization Particles Market?
North America dominated the global embolization particles market generating highest revenue in 2024. High burden of target diseases such as cancer and peripheral vascular diseases, well-established healthcare infrastructure equipped with advanced diagnostic technologies, rising disposable incomes, continuous innovations in medical devices and other healthcare technologies are the factors driving the region’s market dominance. Presence of key market players, increased regulatory approvals and supportive reimbursement policies like Medicare coverage in U.S. are fuelling the market expansion.
Asia Pacific is expected to register the fastest growth in the global embolization particles market over the forecast period. The region’s huge population with aging individuals and rising chronic diseases burden is creating the demand for minimally invasive procedures such as embolization for enhancing patient safety and improving outcomes. Many APAC countries are investing heavily for advancing healthcare infrastructure and adoption of latest medical technologies to improve patient access to effective and safe treatments. Rise of medical tourism in countries like India, China, Singapore and Thailand due to low cost of embolization procedures is contributing to the market growth.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Embolization Particles Market
By Product Type
By Application
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers